Telix Pharmaceuticals Ltd Price, Chart & Factor Exposure
Free Data & Analytics AccessTelix Pharmaceuticals Ltd Forecast
Telix Pharmaceuticals Ltd short-term momentum is strongly negative (up over 0 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term SELL signal. The long-term trend is strongly negative (0 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term SELL signal. Based on 20-day realised volatility of 35.9% a year, a typical one-standard-deviation range is 12.27–13.57 over a week, 11.58–14.26 over a month and 8.2854–17.55 over a year. (Signals as of 21 Nov 2026.)
Telix Pharmaceuticals Ltd Price Chart
Telix Pharmaceuticals Ltd Factors
YoY −2.9%
YoY −23.2%
YoY −14.5%
YoY +27.8%
YoY −21.3%
YoY +502.4%
YoY +3.0%
YoY −0.8%
YoY +54.5%
YoY +94.2%
YoY +51.1%
YoY +52.5%
YoY −52.5%
YoY +18.8%
YoY +50.0%
YoY −5.8%
Telix Pharmaceuticals Ltd fundamentals: income statement, balance sheet & cash flow
Telix Pharmaceuticals Ltd reported revenue of 816.7m AUD and net income of -7.2m AUD in FY2025, the year ended 31 December 2025 — revenue up 4.3% and net income down 114.5% on the prior year. Free cash flow was -56.1m AUD. These figures are as reported in the filings, not restated: 13 fiscal years and 44 quarters of history, back to December 1999.
| AUD millions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 816.7 | 783.2 | 502.5 | 160.1 | 7.6 |
| Cost of revenue | 382.9 | 273.5 | 188.2 | 130.8 | 37.4 |
| Gross profit | 433.8 | 509.7 | 314.4 | 29.3 | -29.8 |
| Research & development | 174.0 | 194.6 | 128.8 | 57.9 | 34.1 |
| Selling, general & admin. | 241.7 | — | — | — | 17.3 |
| Operating income | 18.1 | 82.1 | 52.6 | -73.2 | -81.2 |
| EBITDA | 40.2 | 90.1 | 23.1 | -92.8 | -70.1 |
| Interest expense | 37.3 | 21.5 | 1.0 | 0.4 | 0.2 |
| Pre-tax income | -5.4 | 56.1 | 3.1 | -98.6 | -99.0 |
| Income tax | 1.9 | 6.1 | -2.1 | 5.5 | -18.5 |
| Net income | -7.2 | 49.9 | 5.2 | -104.1 | -80.5 |
Download Telix Pharmaceuticals Ltd fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.TLX.AU&statement=all&freq=a&format=csv&years=10
Figures in AUD, statements as filed. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic.
Research on Telix Pharmaceuticals Ltd
Explore MacroFinance macro & markets research and analysis.
Telix Pharmaceuticals Ltd Trading Strategies
31 backtested tactical asset allocation strategies hold EFA (developed markets outside the US), the closest tradable exposure to Telix Pharmaceuticals Ltd; 22 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in EFA | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Butler's Elastic Asset Allocation - Defensive | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Butler's Elastic Asset Allocation - Offensive | Aggressive | Monthly | Premium · upgrade to view | |||
| Momentum Turning Points | Conservative | Monthly | Premium · upgrade to view | |||
| Keller, Butler and Kipnis' Classical Asset Allocation - Offensive | Moderate | Monthly | Premium · upgrade to view | |||
| Financial Mentor's All-Weather Quad Momentum | Aggressive | Monthly | Premium · upgrade to view | |||
| Keller, Butler and Kipnis' Classical Asset Allocation - Defensive | Moderate | Monthly | Premium · upgrade to view | |||
| Livingston's Mama Bear (Muscular Portfolios) | Aggressive | Monthly | Premium · upgrade to view | |||
| Meb Faber's Global Tactical Asset Allocation 13 (GTAA 13) | Conservative | Monthly | Premium · upgrade to view | |||
| David Varadi's Minimum Correlation Portfolio | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
Statistical Distribution of Returns
PlusHow Telix Pharmaceuticals Ltd’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Telix Pharmaceuticals Ltd (Australia)
Telix Pharmaceuticals Ltd is a listed security in Australia. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
More on Talanx AG
Frequently asked questions
What is Telix Pharmaceuticals Ltd?
What is the latest Telix Pharmaceuticals Ltd price?
Is Telix Pharmaceuticals Ltd in an uptrend?
How volatile is Telix Pharmaceuticals Ltd?
What factors affect Telix Pharmaceuticals Ltd?
Which trading strategies trade Telix Pharmaceuticals Ltd?
How are Telix Pharmaceuticals Ltd returns analysed?
Where can I download free Telix Pharmaceuticals Ltd historical data?
Free Telix Pharmaceuticals Ltd historical data (last 10 years)
Browse or instantly download the last 10 years of Telix Pharmaceuticals Ltd daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.TLX.AU&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 12.92 |
| 2026-11-19 | 13.22 |
| 2026-11-18 | 13.21 |
| 2026-11-17 | 13.33 |
| 2026-11-16 | 13.39 |
| 2026-11-13 | 13.58 |
| 2026-11-12 | 13.7 |
| 2026-11-11 | 14.02 |
| 2026-11-10 | 13.8 |
| 2026-11-09 | 13.93 |
About this stock
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.